Jpmorgan Chase & CO Athira Pharma, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 6,620 shares of ATHA stock, worth $4,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,620

Previous 143 4529.37%

Holding current value

$4,369

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$0.42 - $3.43 $2,720 - $22,216	6,477 Added 4529.37%	6,620 $2,000
Q2 2024 Aug 12, 2024	SELL	$1.92 - $2.71 $14,196 - $20,037	-7,394 Reduced 98.1%	143 $0
Q1 2024 May 10, 2024	BUY	$2.24 - $4.15 $16,562 - $30,685	7,394 Added 5170.63%	7,537 $20,000
Q4 2023 Feb 12, 2024	SELL	$1.39 - $2.46 $1,181 - $2,091	-850 Reduced 85.6%	143 $0
Q3 2023 Nov 14, 2023	SELL	$1.9 - $3.16 $76 - $126	-40 Reduced 3.87%	993 $2,000
Q2 2023 Aug 11, 2023	SELL	$2.36 - $3.59 $61,371 - $93,357	-26,005 Reduced 96.18%	1,033 $3,000
Q1 2023 May 18, 2023	BUY	$2.26 - $4.22 $58,861 - $109,909	26,045 Added 2622.86%	27,038 $67,000
Q1 2023 May 11, 2023	SELL	$2.26 - $4.22 $44,076 - $82,302	-19,503 Reduced 95.16%	993 $2,000
Q4 2022 Feb 13, 2023	SELL	$2.76 - $3.71 $1,512 - $2,033	-548 Reduced 2.6%	20,496 $65,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $3,823 - $5,167	1,305 Added 6.61%	21,044 $62,000
Q2 2022 Aug 11, 2022	BUY	$2.74 - $13.43 $654 - $3,209	239 Added 1.23%	19,739 $60,000
Q1 2022 May 11, 2022	BUY	$8.96 - $13.51 $34,666 - $52,270	3,869 Added 24.75%	19,500 $263,000
Q4 2021 Feb 10, 2022	SELL	$9.17 - $16.39 $714,012 - $1.28 Million	-77,864 Reduced 83.28%	15,631 $204,000
Q3 2021 Nov 12, 2021	BUY	$9.15 - $11.09 $855,479 - $1.04 Million	93,495 New	93,495 $877,000

Others Institutions Holding ATHA

# of Institutions

Shares Held

16.9M

Call Options Held

112K

Put Options Held

68K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $25M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Athira Pharma, Inc. Transaction History